E-resources
-
Aplenc, Richard; Meshinchi, Soheil; Sung, Lillian; Alonzo, Todd; Choi, John; Fisher, Brian; Gerbing, Robert; Hirsch, Betsy; Horton, Terzah; Kahwash, Samir; Levine, John; Loken, Michael; Brodersen, Lisa; Pollard, Jessica; Raimondi, Susana; Kolb, Edward Anders; Gamis, Alan
Haematologica, 07/2020, Volume: 105, Issue: 7Journal Article
New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children's Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric patients with newly diagnosed AML. AAML1031 randomized patients younger than 30 years of age with AML to standard treatment with or without bortezomib. All patients received the identical chemotherapy backbone with either four intensive chemotherapy courses or three courses followed by allogeneic hematopoietic stem cell transplantation for high-risk patients. For those randomized to the intervention arm, bortezomib 1.3 mg/m was given on days 1, 4 and 8 of each chemotherapy course. For those randomized to the control arm, bortezomib was not administered. In total, 1,097 patients were randomized to standard chemotherapy (n=542) or standard chemotherapy with bortezomib (n=555). There was no difference in remission induction rate between the bortezomib and control treatment arms (89% 91%, =0.531). Bortezomib failed to improve 3-year event-free survival (44.8±4.5% 47.0±4.5%, =0.236) or overall survival (63.6±4.5 67.2±4.3, =0.356) compared with the control arm. However, bortezomib was associated with significantly more peripheral neuropathy ( =0.006) and intensive care unit admissions ( =0.025) during the first course. The addition of bortezomib to standard chemotherapy increased toxicity but did not improve survival. These data do not support the addition of bortezomib to standard chemotherapy in children with AML. (Trial registered at ).
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.